Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc Stock
A loss of -1.410% shows a downward development for Stoke Therapeutics Inc.
Stoke Therapeutics Inc is currently one of the favorites of our community with 19 Buy predictions and no Sell predictions.
As a result the target price of 33 € shows a slightly positive potential of 13.09% compared to the current price of 29.18 € for Stoke Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Stoke Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | -1.410% | 4.964% | -12.108% | 430.545% | 7.279% | - | - |
| Personalis Inc | -3.920% | -8.905% | -10.174% | 90.963% | -23.501% | 122.050% | -72.443% |
| Immuron | -1.600% | -2.344% | -7.407% | -50.787% | -7.407% | -62.575% | -86.111% |
Comments
Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat